Nurse-administered intravitreal injections of anti-VEGF: study protocol for noninferiority randomized controlled trial of safety, cost and patient satisfaction

Dordi Austeng, Tora Sund Morken, Stine Bolme, Turid Follestad, Vidar Halsteinli, Dordi Austeng, Tora Sund Morken, Stine Bolme, Turid Follestad, Vidar Halsteinli

Abstract

Background: Intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF) now improve or stabilize visual acuity in a number of previously untreatable eye diseases, of which the main are age-related macular degeneration, retinal vein occlusion and diabetic macular edema. Most patients require multiple injections over lengthy periods of time and the prevalence of treatable conditions is increasing. Anti-VEGF IVI normally administered by physicians, therefore represent a considerable workload on ophthalmologic clinics and will continue to do so in the near future. Nurse-administered IVI may relieve this workload, but the safety, cost and patient satisfaction of such an extended role for nurses in ophthalmologic clinics has not earlier been investigated. To investigate these outcomes following independent anti-VEGF IVI by trained nurses, a noninferiority randomized controlled trial is being conducted.

Methods/design: Patients eligible for anti-VEGF treatment, minimum 304, are recruited and randomized to IVI administration by either trained nurses or physicians. The primary outcome is safety, measured by difference in mean change in visual acuity between the two groups during an observation period of 12 months. Secondary outcomes are incidence of ocular adverse events, cost per patient and patient satisfaction.

Discussion: This study protocol describes the design of the first randomized controlled trial of nurse-administered IVI of anti-VEGF. The study is designed to examine safety, cost and patient satisfaction during 12 months follow-up.

Trial registration: ClinicalTrials.gov NCT02359149 . Registered February 4, 2015.

Keywords: Age-related macular degeneration; Anti-VEGF; Diabetic macular edema; Intravitreal injection; Nurse; Randomized controlled trial; Retinal vein occlusion.

Figures

Fig. 1
Fig. 1
Flowchart. Overview of the enrollment and follow-up of study participants

References

    1. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;8
    1. Braithwaite T, Nanji AA, Lindsley K, Greenberg PB. Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Database Syst Rev. 2014;5
    1. Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev. 2014;10
    1. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44. doi: 10.1056/NEJMoa062655.
    1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31. doi: 10.1056/NEJMoa054481.
    1. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol. 2003;87:312–7. doi: 10.1136/bjo.87.3.312.
    1. Jonas JB, Bourne RRA, White RA, Flaxman SR, Keeffe J, Leasher J, et al. Visual impairment and blindness due to macular diseases globally: a systematic review and meta-analysis. Am J Ophthalmol. 2014;158:808–15. doi: 10.1016/j.ajo.2014.06.012.
    1. The CATT Research Group. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98. doi: 10.1016/j.ophtha.2012.03.053.
    1. Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B, et al. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: two-year results. Ophthalmology. 2015 Oct 15. doi: 10.1016/j.ophtha.2015.09.018. [Epub ahead of print]
    1. Resnikoff S, Felch W, Gauthier TM, Spivey B. The number of ophthalmologist in practice and training worldwide: a growing gap despite more than 200 000 practitioners. Br J Ophthalmol. 2012;96:783–7. doi: 10.1136/bjophthalmol-2011-301378.
    1. Simcock P, Kingett B, Mann N, Reddy V, Park J. A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners. Eye. 2014;28:1161–4. doi: 10.1038/eye.2014.153.
    1. DaCosta J, Hamilton R, Nago J, Mapani A, Kennedy E, Luckett T, et al. Implementation of a nurse-delivered intravitreal injection service. Eye. 2014;28:734–40. doi: 10.1038/eye.2014.69.
    1. Michelotti MM, Abugreen S, Kelly SP, Morarji J, Myerscough D, Boddie T, et al. Transformational change: nurses substituting for ophthalmologists for intravitreal injections—a quality-improvement report. Clin Ophthalmol. 2014;8:755–61.
    1. Varma D, Lunt D, Johnson P, Stanley S. A novel approach to expanding the role of nurses to deliver intravitreal injections for patients with age-related macular degeneration. Int J Ophthalmic Pract. 2013;4:68–74. doi: 10.12968/ijop.2013.4.2.68.
    1. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Arch Ophthalmol. 1999;117:1329–45. doi: 10.1001/archopht.117.10.1329.
    1. The Norwegian Knowledge Centre for the Health Services. . Accessed 20 Aug 2014.
    1. Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG. Reporting of noninferiority and equivalence randomized trials. Extension of the CONSORT 2010 Statement. JAMA. 2012;308:2594–604. doi: 10.1001/jama.2012.87802.
    1. The CATT Research Group. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908. doi: 10.1056/NEJMoa1102673.
    1. Csaky KG, Richman EA, Ferris FL. Report from the NEI/FDA ophthalmic clinical trial design and endpoints symposium. IOVS. 2008;49:479–89.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir